NanoViricides Has Initiated Genetic Toxicology Testing Required for an IND for Its Drug Candidate

SHELTON, CT / ACCESSWIRE / January 7, 2020 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”) a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that it has contracted and initiated genetic toxicology testing required to support the IND application for NV-HHV-101 moving towards human clinical trials.

The Company previously contracted an external laboratory to conduct the studies to assess the genetic toxicologic safety potential of our lead drug candidate, namely NV-HHV-101. These studies include the standard Ames test that utilizes bacterial cells to determine if the drug candidate causes mutations, and also the standardized “micronucleus test” to determine if the drug candidate causes damage to the chromosomes in human cells. The FDA and other international regulatory authorities require these genetic toxicological studies to support the Investigational New Drug (IND) Applications for entering human clinical trials. We are advised that these studies have been completed and we anticipate the results shortly.

After receiving all of the reports from the various required IND-enabling studies, the Company anticipates filing an IND with the US FDA to advance NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication. This indication alone has an estimated market size in billion dollars range.

The Company also continues to evaluate this broad-spectrum drug candidate as well as certain variations based on the same candidate, for the treatment of other herpesviruses, namely HSV-1 cold sores and HSV-2 genital herpes. The market size for our immediate target drugs in the HerpeCide™ program is variously estimated into several billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide™ program, namely, HSV-1 “cold sores” treatment, and HSV-2 “genital ulcers” treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration.

Contact:
NanoViricides, Inc.
Anil R. Diwan
[email protected]

Public Relations Contact:
MJ Clyburn

TraDigital IR
[email protected]

SOURCE: NanoViricides, Inc.

View source version on accesswire.com:
https://www.accesswire.com/572263/NanoViricides-Has-Initiated-Genetic-Toxicology-Testing-Required-for-an-IND-for-Its-Drug-Candidate

error: Content is protected !!